We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
+18.88%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$219M
Cap. Flow
-$413M
Cap. Flow %
-25.11%
Top 10 Hldgs %
53.34%
Holding
74
New
16
Increased
18
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$65.6M
2
MJN
Mead Johnson Nutrition Company
MJN
+$48.9M
3
AEGR
Aegerion Pharmaceuticals
AEGR
+$32.5M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$31.9M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$30.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$92.3M
2
ZBH icon
Zimmer Biomet
ZBH
+$77.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$62.1M
4
AGN
Allergan plc
AGN
+$54.4M
5
ABBV icon
AbbVie
ABBV
+$47M

Sector Composition

Rank Sector Weight
1 Healthcare 59.57%
2 Consumer Staples 9.02%
3 Financials 4.8%
4 Materials 0.45%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
51
Alkermes
ALKS
$8.22B
– –
-825,000
Closed -$27.7M
CCEP icon
52
Coca-Cola Europacific Partners
CCEP
$48.3B
– –
-200,000
Closed -$8.04M
CLDX icon
53
CALL
Celldex Therapeutics
CLDX
$2.99B
– –
-20,000
Closed -$10.6M
CLDX icon
54
Celldex Therapeutics
CLDX
$2.99B
– –
-1,753
Closed -$932K
COO icon
55
Cooper Companies
COO
$14.1B
– –
-87,876
Closed -$2.85M
CRVL icon
56
CorVel
CRVL
$3.06B
– –
-654,000
Closed -$8.06M
DOC icon
57
Healthpeak Properties
DOC
$15.1B
– –
-73,895
Closed -$2.76M
ELV icon
58
Elevance Health
ELV
$81.5B
– –
-175,000
Closed -$14.6M
EW icon
59
Edwards Lifesciences
EW
$49.6B
– –
-3,000,000
Closed -$34.8M
GILD icon
60
PUT
Gilead Sciences
GILD
$162B
– –
-1,251,500
Closed -$78.7M
LLY icon
61
Eli Lilly
LLY
$1.02T
– –
-121,929
Closed -$6.14M
MTD icon
62
Mettler-Toledo International
MTD
$28.6B
– –
-12,514
Closed -$3M
PFE icon
63
Pfizer
PFE
$143B
– –
-248,217
Closed -$6.76M
PTCT icon
64
PTC Therapeutics
PTCT
$5.68B
– –
-732,200
Closed -$15.7M
SRPT icon
65
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-150,000
Closed -$7.08M
SRPT icon
66
PUT
Sarepta Therapeutics
SRPT
$1.57B
– –
-200,000
Closed -$9.45M
ZTS icon
67
Zoetis
ZTS
$32.4B
– –
-675,000
Closed -$21M
CMRX
68
DELISTED
Chimerix, Inc.
CMRX
– –
-300,000
Closed -$6.59M
AET
69
DELISTED
Aetna Inc
AET
– –
-700,000
Closed -$44.8M
IPXL
70
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-1,112,400
Closed -$22.8M
PCYC
71
PUT
DELISTED
PHARMACYCLICS INC
PCYC
– –
-200,000
Closed -$27.7M
SLXP
72
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-245,300
Closed -$16.4M
CBST
73
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-900,000
Closed -$57.2M
ITMN
74
DELISTED
INTERMUNE INC
ITMN
– –
-271,100
Closed -$4.17M
1 2
3

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q4 2013 Portfolio in Review

As of Q4 2013, HealthCor Management held 74 positions worth $1.65B, down 12% from $1.87B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

HealthCor Management withdrew a net $413M in Q4 2013, closing 25 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, HealthCor Management opened a new position in Mead Johnson Nutrition Company worth $50.3M.

  • HealthCor Management's largest Q4 2013 buy was Mead Johnson Nutrition Company: 600,000 shares worth $50.3M.
  • HealthCor Management added most to McKesson in Q4 2013, an estimated $65.6M increase.
  • HealthCor Management's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $92.3M.
  • HealthCor Management fully exited AbbVie in Q4 2013, selling an estimated $47M.
  • HealthCor Management's ten largest holdings make up 53% of its $1.65B portfolio in Q4 2013.
  • HealthCor Management opened 16 new positions and closed 25 in Q4 2013.
  • HealthCor Management's portfolio value fell 12% quarter-over-quarter to $1.65B.

Based on HealthCor Management's 13F filing for Q4 2013, filed 14 Feb 2014.